Abstract
Non-keratinocyte cutaneous malignancies including breast cancer cutaneous metastasis and melanoma in situ are often poor surgical candidates due to their anatomical location, size and the morbidities associated with surgery. Imiquimod, a toll-like receptor 7 agonist, is used for the treatment of these cutaneous malignancies, which activates the innate immunity in the skin. However, imiquimod’s modest effect on the activation of adaptive immunity limits its efficacy as a monotherapy. We have previously demonstrated that topical induction of thymic stromal lymphopoietin (TSLP) cytokine by calcipotriol protects against skin and breast cancer development by directly activating T cell immunity.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
